Deutsche Telekom AG press release ( DTEGY ): Q1 Adjusted EPS of €0.54 Revenue increased to €29.87B from about €29.76B a year earlier, slightly above consensus of €29.70B. Service revenue, a key telecom metric, rose 0.8% to €25.04B. Net profit declined to €2.04B from €2.85B YoY. Q1 adjusted EBITDAaL rose to €11.52B from €11.30B YoY, ahead of analyst expectations of €11.35B. Deutsche Telekom maintai...
Deutsche Telekom AG press release ( DTEGY ): Q1 Adjusted EPS of €0.54 Revenue increased to €29.87B from about €29.76B a year earlier, slightly above consensus of €29.70B. Service revenue, a key telecom metric, rose 0.8% to €25.04B. Net profit declined to €2.04B from €2.85B YoY. Q1 adjusted EBITDAaL rose to €11.52B from €11.30B YoY, ahead of analyst expectations of €11.35B. Deutsche Telekom maintained adjusted EPS guidance at around €2.20 and expects free cash flow after leases to exceed €19.8B. R aised its FY2026 adjusted EBITDAaL guidance to about €47.5B from €47.4B previously, helped by stronger performance at T-Mobile US . The guidance increase follows T-Mobile US lifting its own 2026 outlook in April on strong demand for premium plans and bundled offerings. More on Deutsche Telekom AG Hold Fairly Valued Deutsche Telekom Shares As An Investment In U.S. Telecoms T-Mobile Is Now More Attractive Than Deutsche Telekom Deutsche Telekom AG (DTEGY) Shareholder/Analyst Call Transcript Rheinmetall, Deutsche Telekom plan to jointly develop drone defense shield Quant snapshot: Beachbody, Deutsche Telekom among top-rated names as IceCure Medical, Fold Holdings lag
Earnings Call Insights: Curis, Inc. (CRIS) Q1 2026 Management View "We continue to make steady progress in our TakeAim Lymphoma study in primary CNS lymphoma" and said the TakeAim Lymphoma study is "a single-arm registrational study with an ORR endpoint" evaluating emavusertib plus ibrutinib after progression on BTKi therapy (President, CEO, Secretary, Treasurer & Director James Dentzer). "After c...
Earnings Call Insights: Curis, Inc. (CRIS) Q1 2026 Management View "We continue to make steady progress in our TakeAim Lymphoma study in primary CNS lymphoma" and said the TakeAim Lymphoma study is "a single-arm registrational study with an ORR endpoint" evaluating emavusertib plus ibrutinib after progression on BTKi therapy (President, CEO, Secretary, Treasurer & Director James Dentzer). "After collaborative discussions with both FDA and EMA, we expect the study to support accelerated submissions in both the U.S. and Europe" and "anticipate providing updated emavusertib clinical data... in the first half of 2027" (President, CEO Dentzer). "We anticipate the dosing of the initial 5 patients in the TakeAim CLL combination study with zanubrutinib by mid-2026, and we expect to have initial data in December" as Curis positions the CLL effort as a proof-of-concept in patients on BTKi monotherapy who are in partial remission but not in complete remission/undetectable MRD (President, CEO Dentzer). "The initial data showed results for 16 evaluable patients, demonstrating both a manageable toxicity profile and encouraging preliminary results" from a collaborator-run gastroesophageal cancer study combining emavusertib with FOLFOX and anti-PD-1 plus/minus Herceptin (President, CEO Dentzer). "Curis reported a net loss of $24.2 million or $1.25 per share for the first quarter of 2026" and said the larger loss versus the prior-year quarter was "primarily due to a change in fair value of warrant liabilities associated with the January 2026 PIPE financing" (CFO and Principal Financial & Accounting Officer Diantha Duvall). Outlook "We anticipate providing updated emavusertib clinical data" from the PCNSL TakeAim Lymphoma combination study "in the first half of 2027" and said Curis is aiming for accelerated submissions in the U.S. and Europe supported by that registrational single-arm ORR study (President, CEO Dentzer). "We anticipate the dosing of the initial 5 patients" in TakeAim ...
Earnings Call Insights: GCT Semiconductor Holding, Inc. (GCTS) Q1 2026 Management View "In the first quarter, we delivered 3,000 5G chipsets, a sequential increase of 58% versus Q4," said President, CEO & Director John Schlaefer, framing the quarter as customers move "through the final stages of testing and into initial deployments" while emphasizing shipment volume is still "modest relative to th...
Earnings Call Insights: GCT Semiconductor Holding, Inc. (GCTS) Q1 2026 Management View "In the first quarter, we delivered 3,000 5G chipsets, a sequential increase of 58% versus Q4," said President, CEO & Director John Schlaefer, framing the quarter as customers move "through the final stages of testing and into initial deployments" while emphasizing shipment volume is still "modest relative to the long-term opportunity ahead." Schlaefer highlighted expansion beyond early 5G ramps into multiple use cases: "We continue to support a growing number of programs across multiple verticals, FWA, IoT, and NTN," and said engagements can extend "beyond traditional licensing into deeper platform-level collaboration." On the satellite opportunity, Schlaefer said, "we expanded our previously announced engagement with one of the world's largest satellite communication providers to fast-track global 5G deployment through a reference platform agreement," adding, "Initial 5G chipset shipments to this partner remain on track to begin in the second half of 2026." "Net revenues increased by $1.4 million or 287% from $0.5 million... to $1.9 million," said Chief Financial Officer Fong Cheng, attributing it to "an increase of $0.4 million in product sales and an increase of $1 million in service revenues." Outlook Schlaefer reiterated expected shipment trajectory while flagging timing uncertainty: "we continue to expect sequential growth in 5G chipset shipments as commercialization continues to scale throughout the year" but "the timing and pace of deployments can vary as customers finalize their rollout plans." Management provided margin expectations tied to mix shift. Schlaefer said, "we've often said that the gross margin coming from the products... would be in the 35% and growing into the low 40s," and CFO Cheng added, "once the chipset sales grows significantly, it would normalize to the high 30s to low 40s." On operating spend cadence, CFO Cheng said, "we expect in the second half o...